Navigation Links
MaxLife Fund Corp. announces cancellation of 14,050,000 Common Shares
Date:8/5/2009

NEW JERSEY, Aug. 5 /PRNewswire-FirstCall/ - MaxLife Fund Corp. (OTC:MXFD), have announced that some of its founding shareholders have agreed to cancel a total of 14,050,000 shares of the Company's common stock in order to increase overall shareholder value for the Company.

Bennett Kurtz, Chief Executive Officer of the Company says: "We believe this is a very important step for our Company to increase shareholder value and support future growth. This comes at an exciting opportunistic time, when MaxLife is launching a new and innovative life settlement product (information can be found at www.themxway.com). The early reaction to this product is very positive and should contribute revenues in the near future. We believe that this combination of the reduced shares outstanding and the anticipated bottom line growth should have a positive effect for our shareholders." The Company is currently in negotiations with other shareholders to cancel more shares as well and such shareholders may receive options and/or warrants in the Company in consideration for cancelling their shares.

About MaxLife Fund Corp.: MaxLife Fund Corp. is concentrating on 3 major components of the fast growing Life Settlement sector; (1) to invest and trade policies for our own inventory, (2) to obtain ownership in companies in the life settlement industry and (3) to build a large portfolio by demand for institutional buyers.

The MX-Series Life Settlement product is a new way for investors, hedge funds and pension funds to participate in the sector with secure minimum returns and potential for higher maximum returns. This is a way for such investors to diversify into an alternative asset class.

MaxLife Fund Corp. is positioning itself to grow with the industry and expand its operation to become one of the leaders in the Life Settlement sector.

Cautionary Statement Pursuant to Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties. The actual results that the Company achieves may differ materially from any forward-looking statements due to such risks and uncertainties. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this news release.

    For further information contact:
    MaxLife Fund Corp.

    Tel: 1-866-752-5557
    Email: info@themxway.com
    www.maxlifefund.com


'/>"/>
SOURCE MaxLife Fund Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares
2. MaxLife Fund Corp. declares dividends to shareholders of Preferred Shares.
3. MaxLife Fund Corp. Appoints Mr. Dan Schmitt, Mr. Randy Delkus and Mr. Daniel E. Kahan to its Board of Directors
4. MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement
5. MaxLife Fund Corp. retains the Law firm, Anslow & Jaclin, LLP of Manalapan, N.J., to review MaxLife Fund Corp. options to be listed on the NASDAQ Capital Market
6. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
7. MaxLife Fund Corp. purchases a portfolio of Life Settlement Policies with a face value of $4,000,000
8. BBV Vietnam S.E.A. Acquisition Corp. Announces Signing of Letter of Intent for Business Combination with Migami, Inc.
9. HMS Holdings Corp. Announces Q2 2009 Results and Raises 2009 Guidance
10. Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. Announce Merger Agreement
11. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... and Consulting, LLC , and named its founder as ... in Tennessee , will operate under ... EnvoyHealth,s service offerings for health care partners to include ... "In an interoperable world, technology delivers ...
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: